Continuous dopaminergic therapy in Parkinson disease: time to stride back?
Stoessl
A Jon
AJ
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000453:epidemiology; D013997:Time Factors
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D009570:Nitriles; C071192:entacapone; D002394:Catechol O-Methyltransferase